Full Text View
Tabular View
No Study Results Posted
Related Studies
Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg (Micardis Plus) Ambulatory Blood Pressure Monitoring (ABPM) Study in China
This study has been completed.
Study NCT00257491   Information provided by Boehringer Ingelheim Pharmaceuticals
First Received: November 22, 2005   Last Updated: September 24, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypertension
More general conditions related to this trial
Cardiovascular Diseases
Vascular Diseases
Interventions listed in this trial
Telmisartan
Telmisartan/HCTZ
Additional drug interventions recognized in this trial
Hydrochlorothiazide
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Cardiovascular Agents
Diuretics
Enzyme Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sodium Chloride Symporter Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services